IQSEC1 Knockout A-549 Polyclonal Cells are a CRISPR/Cas9-edited polyclonal knockout cell population derived from the A-549 lung adenocarcinoma line. They present a heterogeneous pool with targeted disruption of IQSEC1, offering a loss-of-function model free from clonal selection artifacts. This polyclonal format ensures representation of diverse genetic backgrounds, making it ideal for robust pathway analysis and phenotypic screening.
The A-549 cell line is a well-established epithelial model of lung adenocarcinoma, isolated from human alveolar basal epithelial adenocarcinoma. It retains critical features of invasive carcinoma, including EGFR and integrin expression, and is extensively used in cancer metastasis studies. As an adherent lung cancer cell model, A-549 provides a relevant context for investigating genes that regulate adhesion, migration, and intracellular trafficking.
IQSEC1, also known as BRAG2, acts as a guanine nucleotide exchange factor (GEF) for ARF6, catalyzing GTP loading and activation. Active ARF6 promotes endosomal recycling and actin cytoskeletal remodeling through effectors such as PIP5K, which generates PIP2, and Rac1, leading to actin polymerization. Upstream, IQSEC1 is regulated by integrins, EGFR, and receptor tyrosine kinases, often via calmodulin. It interacts with calmodulin, PIP5K, and cortactin to coordinate membrane trafficking and actin dynamics, ultimately controlling cell adhesion and migration. Thus, IQSEC1 is a key integrator of extracellular signals that drive ARF6-dependent cytoskeletal rearrangements.
In A-549 cells, which possess an intact ARF6 signaling axis, IQSEC1 disruption is anticipated to impair ARF6 activation and downstream events. This provides a physiologically relevant system to dissect the GEF’s role in lung cancer cell behaviors including invasion and metastasis. The model is particularly valuable for studying how integrin-mediated adhesion, endocytosis, and actin dynamics collectively contribute to tumor cell dissemination in an adenocarcinoma background.
Researchers can utilize IQSEC1 Knockout A-549 Polyclonal Cells in diverse assays, including western blotting and RT-qPCR for gene disruption verification, immunofluorescence for protein localization, and transwell migration and invasion assays for phenotypic analysis. ARF6 activity pull-down and actin staining enable direct assessment of the ARF6 pathway, while endocytosis assays reveal trafficking defects. These cells are also suitable for drug response screening to evaluate IQSEC1-dependent therapeutic sensitivity. For additional information, please contact Ascent Research.
